Krunamina Side effects

• Side effects of Krunamina in details
• Krunamina contraindications
• Krunamina reviews

What are the possible side effects of Krunamina?

Get emergency medical help if the patient has signs of an allergic reaction: hives; difficult breathing; swelling of the face, lips, tongue, or throat.

Tell the medical caregivers right away if the person receiving Krunamina has:

• agitation, signs of waking up, or any change in level of consciousness;

• slow heartbeats;

• weak or shallow breathing, cough;

• feeling light-headed or short of breath;

• muscle weakness; or

• pale or blue-colored skin.

Certain side effects may occur during the first 48 hours after the patient stops receiving Krunamina. Call the doctor right away if the patient has any of the following side effects:

• headache, confusion, anxiety, feeling nervous or agitated;

• weakness, feeling light-headed or short of breath;

• stomach pain, diarrhea, constipation;

• excessive sweating;

• weight loss;

• blurred vision, pounding in the neck or ears;

• severe chest pain, rapid or irregular heartbeats; or

• an unusual craving for salt.

Common side effects may include:

• slowed breathing;

• slow or irregular heartbeats;

• anemia;

• dry mouth, nausea;

• fever; or

• dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Krunamina in details

Applies to Krunamina: parenteral injection concentrate

Side effects include:

Hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia, anemia.

What is the most important information I should know about Krunamina?

Before Krunamina is given, the doctor should know about all the patient's medical conditions or allergies, and all other medicines the patient is using. Also make sure the doctor knows if the patient is pregnant or breast-feeding.

Krunamina contraindications

There are no contraindications listed in the US manufacturer's labeling.

Canadian labeling: Hypersensitivity to Krunamina or any component of the formulation.

References

1. European Chemicals Agency - ECHA. "5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
2. NCIt. "Dexmedetomidine: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
3. KEGG. "Target-based classification of drugs". http://www.genome.jp/kegg-bin/get_ht... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Krunamina are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Krunamina. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology